Pharmaceuticals
Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants
MELBOURNE, Australia, June 18, 2021 /PRNewswire/ -- New data released today
shows thatAustralia's Viraleze™ anti-COVID nasal spray is more than 99.9%
effective against three of the four deadliest variants of the SARS-CoV-2 virus.
2021-06-18 14:04
14848
Gilead Sciences Announces Subanalyses of Safety and Efficacy Data from a Phase 2 Study of Chronic Hepatitis B Patients with Renal or Hepatic Impairment Switching to Vemlidy(r)
HONG KONG, June 18, 2021 /PRNewswire/ -- Gilead Sciences, Inc. today announced new sub-analysis data from a Phase 2 open-label study (GS-US-320-4035; NCT03180619), evaluating the safety and efficacy of switching to Vemlidy®# (tenofovir alafenamide 25 mg, TAF) from tenofovir disoproxil fumarate (T...
2021-06-18 10:00
2527
Jacobio Announces First Two Patients Dosed in SHP2 Combination Study, Triggering US$20 Million Milestone Payment
BEIJING and SHANGHAI and BOSTON, June 18, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) has announced that the first two patients have been dosed in the Phase 1/2a clinical trial ofSHP2 inhibitor JAB-3312 in combination with PD-1 antibody Pembrolizumab and MEK inhibitor Binimetinib respe...
2021-06-18 08:31
5210
Innovent Announces First Patient Dosed in the Phase II Basket Trial of Taletrectinib for Solid Tumors with NTRK Fusion
SAN FRANCISCO and SUZHOU, China, June 18, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...
2021-06-18 08:00
4060
Envirotainer Announces Cathay Pacific as First Asian carrier for the recently released Releye® RLP container
STOCKHOLM, June 17, 2021 /PRNewswire/ -- Envirotainer, the global market leader in secure cold chain solutions for air transportation of pharmaceuticals, today announced that Cathay Pacific has approved the Envirotainer Releye® RLP for carriage on its fleet of aircraft. Cathay Pacific can now off...
2021-06-17 19:49
1978
Elekta radiotherapy system designed for changing cancer landscape now available for U.S. patients
ATLANTA, June 17, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that its Elekta Harmony* radiation therapy system recently received U.S. FDA 510(k) clearance, paving the way for U.S. clinics to harness the system to treat a comprehensive range of indications using the latest radiotherap...
2021-06-17 14:38
15914
Gannex Announces Positive Topline Results of the U.S. Phase I Trial of NASH Drug ASC42, an FXR Agonist
SHANGHAI, June 16, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), fully dedicated to the R&D and commercialization of new drugs in the field of non-alcoholic steatohepatitis (NASH), today announces positive topline results of safety and pharmacodynamic ...
2021-06-16 21:00
3932
Galimedix Accelerating Development of Its Next-Generation Oral Anti-Amyloid Beta Drug GAL-201 for Alzheimer's Disease
Following recent FDA approval of Biogen's Alzheimer antibody drug ADUHELM (TM), targeting oligomers of amyloid beta, Galimedix aims for first patients with its GAL-201 oral small molecule drug within one year. KENSINGTON, Md., June 16, 2021 /PRNewswire/ -- Galimedix, Inc., a clinical-stage bioph...
2021-06-16 04:38
1288
VNTC confirms Dong-A ST its sole distributor of scoliosis brace Spinamic in South Korea
SEOUL, South Korea, June 15, 2021 /PRNewswire/ -- VNTC, a MedTech company, announced onJune 15 its signing of a Korean distributorship contract with Dong-A ST. The two companies are now able to provide a wide range of services both at home and abroad through mutual cooperation in sales and market...
2021-06-16 00:00
3667
Frontera Therapeutics Starts GMP Manufacturing Facility Construction
SUZHOU, China, June 15, 2021 /PRNewswire/ -- On June 9, 2021, Frontera Therapeutics Co., Ltd. ('Frontera') held a groundbreaking ceremony to start the construction of its Suzhou facility in bioBAY of Suzhou Industrial Park (SIP), Jiangsu, China. President of Suzhou Frontera, Dr. Xinyan Li, hosted ...
2021-06-15 23:32
2157
Qynapse to present clinical results of QyScore® for Alzheimer's Disease and Multiple Sclerosis at the 7th Congress of the European Academy of Neurology
BOSTON, June 15, 2021 /PRNewswire/ -- QYNAPSE Inc., a medical technology company commercializing the most advanced artificial intelligence neuroimaging platform, today announced it will present clinical data on QyScore® for Alzheimer's disease and multiple sclerosis at the 7th Congress of the Eur...
2021-06-15 18:00
2925
Innovent Announces First Overweight or Obese Subject Dosed in A Phase 2 Clinical Trial of IBI362 (a GLP-1 and Glucagon Receptor Dual Agonist) in China
SAN FRANCISCO and SUZHOU, China, June 15, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...
2021-06-15 12:00
5133
Ascentage Pharma Announces IND Clearance by the US FDA for Lisaftoclax (APG-2575) as Single Agent or in Combinations for the Treatment of ER+ Breast Cancer and Other Solid Tumors
SUZHOU, China, and ROCKVILLE, Md., June 15, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Investigational Ne...
2021-06-15 07:39
18036
Bridge Biotherapeutics Announces the Initiation of Patient Dosing in the Proof of Clinical Principle Study for BBT-401, an Investigational Drug for Ulcerative Colitis
SEONGNAM, South Korea, June 13, 2021 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330) announced today the first patient dosing of BBT-401 at mid to high doses in its proof of clinical principle (PoCP) study to examine the drug's efficacy and safety in active ulcerative colitis (NCT04596293). Th...
2021-06-14 06:00
2559
ImmVira completed the first dosing for Phase II of MVR-T3011 (intratumoral injection) in the U.S. and China
SHENZHEN, China, June 11, 2021 /PRNewswire/ -- ImmVira announced that in the Phase II Clinical Trials of its leading oncolytic virus product, MVR-T3011* as intratumoral administration (MVR-T3011 IT), ImmVira has completed the first dosing in bothChina and the U.S. on May 28 2021 and June 11 20...
2021-06-12 11:16
3561
Viraleze registered for sale in Covid-ravaged India
MELBOURNE, Australia, June 11, 2021 /PRNewswire/ -- India's vast population
will have access from today to the Australian developed anti-COVID nasal spray
Viraleze™ following its registration in the country.
2021-06-11 15:15
13939
Viraleze registered for sale in Covid-ravaged India
MELBOURNE, Australia, June 11, 2021 /PRNewswire/ -- India's vast population
will have access from today to the Australian developed anti-COVID nasal spray
Viraleze™ following its registration in the country.
2021-06-11 15:03
2091
Long-lasting Chlorine Dioxide (ClO2) Aqueous Solution Presented by Taiko Pharmaceutical and Kitasato University Inactivates over 99.99% of SARS-CoV-2 (COVID-19 Virus)
OSAKA, Japan, June 11, 2021 /PRNewswire/ -- Taiko Pharmaceutical Co., Ltd. based inOsaka, Japan, hereby announced that long-lasting chlorine dioxide (ClO2) aqueous solution (*1) inactivated over 99.99% of SARS-CoV-2 (COVID-19 Virus), including its Alpha and Gamma variants (*2), in a test conducte...
2021-06-11 14:00
2572
Long-lasting Chlorine Dioxide (ClO2) Aqueous Solution Presented by Taiko Pharmaceutical and Kitasato University Inactivates over 99.99% of SARS-CoV-2 (COVID-19 Virus)
OSAKA, Japan, June 11, 2021 /PRNewswire/ -- Taiko Pharmaceutical Co., Ltd. based inOsaka, Japan, hereby announced that long-lasting chlorine dioxide (ClO2) aqueous solution (*1) inactivated over 99.99% of SARS-CoV-2 (COVID-19 Virus), including its Alpha and Gamma variants (*2), in a test conducte...
2021-06-11 14:00
3049
Yingli Pharma Announces a presentation on the Phase 2 clinical trial of linperlisib, a PI3Kδ selective inhibitor, in relapsed or refractory follicular lymphoma at the European Hematology Association 2021 Congress
SHANGHAI, June 11, 2021 /PRNewswire/ -- Shanghai Yingli Pharmaceuticals Ltd (Yingli Pharma), a clinical stage pharmaceutical company providing new therapies for cancer and metabolic diseases, announced today the topline data from a clinical trial sponsored by the company at the annual meeting of ...
2021-06-11 13:05
2934
Week's Top Stories
Most Reposted
Agoda Opens New Office at One Bangkok, Enhancing Its Technology Hub in Thailand
[Picked up by 321 media titles]
2026-04-09 13:00
Visa Opens the Door to AI-Driven Shopping for Businesses Worldwide
[Picked up by 312 media titles]
2026-04-09 09:00Sustainable Tourism Impact Fund Expands Investments Across Southeast Asia
[Picked up by 309 media titles]
2026-04-03 11:30
Visa cements global K-pop connection as Worldwide Tour Sponsor for "BTS WORLD TOUR 'ARIRANG'"
[Picked up by 307 media titles]
2026-04-06 10:00
UTP Advances Across Key Disciplines in QS World University Rankings By Subject 2026 - Petroleum Engineering Among World's Top 10
[Picked up by 299 media titles]
2026-04-06 16:46
Most Read
Korea's Supreme Court Upholds Korea Zinc's Voting Restriction, Rebuffing Young Poong's Legal Challenge
2026-04-03 21:00
5970
51Talk Marks 15 Years with Global Brand Refresh and Names Thai Actor, Shahkrit Yamnarm as Brand Ambassador in Thailand
2026-04-03 11:00
5931
Xinhua Silk Road: Global South financiers visit E. China's Ningbo to explore industrial and cultural innovation
2026-04-03 20:02
5504
Ridgetech, Inc. Announces 1-for-150 Reverse Share Split
2026-04-04 00:00
5385
